Bimekizumab
Monoclonal antibody used in the treatment of psoriasis
| Bimekizumab | |
|---|---|
| File:Bimekizumab.png | |
| INN | |
| Drug class | |
| Routes of administration | Subcutaneous |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Rx-only |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Bimekizumab is a monoclonal antibody used in the treatment of psoriasis and other inflammatory conditions. It is marketed under the trade name Bimzelx. Bimekizumab works by selectively inhibiting the activity of interleukin-17A (IL-17A) and interleukin-17F (IL-17F), which are cytokines involved in inflammatory processes.
Mechanism of Action
Bimekizumab is a biologic therapy that targets and neutralizes IL-17A and IL-17F. These cytokines are part of the interleukin-17 family, which plays a crucial role in the pathogenesis of autoimmune diseases such as psoriasis. By inhibiting these cytokines, bimekizumab reduces inflammation and the symptoms associated with psoriasis.
Clinical Use
Bimekizumab is primarily used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is administered via subcutaneous injection.
Administration
The recommended dosage of bimekizumab is an initial dose followed by maintenance doses at regular intervals. The specific dosing schedule may vary based on the patient's response and the prescribing physician's recommendations.
Side Effects
Common side effects of bimekizumab include upper respiratory tract infections, headache, and injection site reactions. Serious side effects may include increased risk of infections, such as tuberculosis, and hypersensitivity reactions.
Contraindications
Bimekizumab is contraindicated in patients with known hypersensitivity to the drug or any of its components. It should be used with caution in patients with a history of chronic infections or those who are immunocompromised.
Related Pages
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
